Cost savings with theta burst stimulation Cost savings with theta burst stimulation

Theta burst stimulation: Significant cost-savings

iTBS depression treatment leads to cost-savings

Significant cost savings with theta burst stimulation

3 minute depression treatment sessions using theta burst stimulation is not only an advantage for the patient who has to spend less time in the doctor’s office. A new cost analysis shows that it is also great news for the health care system because of lower treatment costs.

The cost-savings associated with the 3 minute theta burst sessions are significant compared to the standard protocol– both when it comes to costs per patient and cost per remission. This is the result of a cost analysis based on patient-level data from the groundbreaking THREE-D trial published in the Lancet in 2018. The researchers have scrutinized the data to conduct a cost analyses from a healthcare system perspective in order to compare the direct treatment costs per course and per remission for the 3 minute theta burst protocol (iTBS) versus the 37 minute standard TMS protocol.

The average cost per patient was USD 1.108 for a treatment course consisting of 3 minute sessions, whereas the price was USD 1.844 for the 37 minute, standard TMS protocol. The average cost per remission was USD 3.695 for iTBS and USD 6.146 for standard TMS – which is a difference of USD 2.451. According to the cost analysis, the reasons for these significant cost-savings associated with the short 3 minute iTBS stimulation can be attributed to the shorter treatment sessions and increase in treatment capacity. The research- ers used direct healthcare costs associated with the equipment, coils, physician assessments and technician time over the course of the treatment to establish all costs involved in the treatment.

More info about the studies
Implementation of intermittent theta burst stimulation compared to conventional repetitive transcranial magnetic stimulation in patients with treatment resistant depression: A cost analysis

Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial (publised in the Lancet)

The article was originally printed in TMS Update by MagVenture Issue 1. The views and opinions expressed in this article do not necessarily reflect the official policy or position of MagVenture or any of its affiliates. The usage of rTMS for any other purpose than the cleared indication, in the country in which the product is intended to be used, is considered investigational.

Additional Info

  • news-gallery-image: news-gallery-image

contact us

Talk to an expert

Do you need help? Let us know how our experts can help you.

Subscribe to the MagVenture Newsletter

By clicking on the submit button, I confirm that I have read and agree to MagVenture’s Terms of Use.